PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Dr Belinda Solomon describes how a case of Behçet’s disease was picked up in her clinic and explains how to recognise and ...
The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
MedPage Today on MSN
EULAR Updates Its Guidance on Managing Behcet's Syndrome
Takes recent clinical trials, drug introductions into account ...
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy The Phase 2a study, evaluating control of oral ...
PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results